Lauren Merendino
CIK 1855298 · Chief Commercial Officer · last filed 2026-04-23
Lauren Merendino is a Chief Commercial Officer who has filed 18 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for DAWN, was dated Apr 23, 2026. Across all open-market trades the lifetime net is −$343.2K, making them a net seller over the disclosed history. 3 Form 144 notices of planned sales are also on file; the latest, for DAWN on Feb 17, 2026, lists the filer as an officer. 1 sale listed on those notices, worth $48.0K in all, has no matching Form 4.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MYOV price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1800 SIERRA POINT PARKWAY, SUITE 200
BRISBANE, CA 94005
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Chief Commercial Officer | 0 | $21.53 | $0 | -$150.7K | 7 | 2026-04-23 |
| ESSA Pharma Inc. (EPIX) Delisted | Director | — | $0.20 | — | $0 | 1 | 2024-03-28 |
| Myovant Sciences Ltd. (MYOV) Delisted | Chief Commercial Officer | 0 | $26.98 | $0 | -$192.5K | 7 | 2023-03-10 |
Recent Filings
18 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-04-23 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Disp (D) | −60,157 | $0 | EDGAR |
| 2026-02-18 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +9,348 | -$67.4K | EDGAR |
| 2026-02-17 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) Officer · Planned Feb 17, 2026 Sold: Form 4 filed Feb 18, 2026 |
−5,814 | -$67.4K | EDGAR |
| 2026-01-30 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-11-18 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +6,810 | -$33.2K | EDGAR |
| 2025-11-17 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) Officer · Planned Nov 17, 2025 Sold: Form 4 filed Nov 18, 2025 |
−3,726 | -$33.2K | EDGAR |
| 2025-11-07 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | — | $0 | EDGAR |
| 2025-08-19 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +6,770 | -$25.5K | EDGAR |
| 2025-05-19 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +6,609 | -$24.6K | EDGAR |
| 2025-05-16 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) Officer · Planned May 16, 2025 Sold: Form 4 filed May 19, 2025 |
−3,927 | -$24.6K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).
Sales Reported Only on Form 144
1 sale · $48.0K| Sold | Symbol | Shares | Proceeds | Avg Price | Listed On |
|---|---|---|---|---|---|
| 2025-02-18 | DAWN | 4,009 | $48.0K | $11.96 | 2025-05-16 |